Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...
Issued at 4:25 pm EDT on Saturday 30 November 2024 for the period until midnight EDT Saturday 7 December 2024. For latest warnings go to www.bom.gov.au, subscribe to RSS feeds, call 1300 659 210* or ...